UPDATE | May 14, 2026
Samsung Organoids: Validation of a GxP-aligned patient-derived tumor organoid services for drug screening with clinical and multi-omics data
Patient-derived organoids (PDOs) are increasingly recognized as physiologically relevant ex vivo models for evaluating drug response while preserving tumor heterogeneity and patient-specific characteristics.
This poster introduces Samsung Organoids, a GxP-aligned PDO-based screening service developed in collaboration with Samsung Medical Center (SMC), integrating source tumor tissues, anonymized clinical records, and multi-omics data to support more predictive drug screening approaches.
Key highlights:
Recapitulation of tumor mutations and patient-specific drug responses
82.6% concordance with clinical treatment outcomes
Integrated multi-omics analysis supporting insights into treatment sensitivity and resistance
GxP-aligned organoid screening workflows designed to support translational oncology research
Discover how integrated organoid and multi-omics approaches can support more informed and data-driven decision-making in precision oncology.
Patient-derived organoids (PDOs) are increasingly recognized as physiologically relevant ex vivo models for evaluating drug response while preserving tumor heterogeneity and patient-specific characteristics.
This poster introduces Samsung Organoids, a GxP-aligned PDO-based screening service developed in collaboration with Samsung Medical Center (SMC), integrating source tumor tissues, anonymized clinical records, and multi-omics data to support more predictive drug screening approaches.
Key highlights:
- Recapitulation of tumor mutations and patient-specific drug responses
- 82.6% concordance with clinical treatment outcomes
- Integrated multi-omics analysis supporting insights into treatment sensitivity and resistance
- GxP-aligned organoid screening workflows designed to support translational oncology research
Discover how integrated organoid and multi-omics approaches can support more informed and data-driven decision-making in precision oncology.
Related Content